−0.0455USD
−131.00 KUSD
7.79 MUSD
3.70 M
About International Stem Cell Corp.
Sector
Industry
CEO
Andrey Semechkin
Website
Headquarters
San Diego
Employees (FY)
29
Founded
2005
FIGI
BBG000BNH2G6
International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of human parthenogenetic stem cells for the treatment of various diseases of the central nervous system and liver diseases. The firm operates through three segments: Therapeutic Market, Biomedical Market and Anti-Aging Market. The Biomedical Market segment markets and sells primary human cell research products with two product categories, cells and media. The Anti-Aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ISCO is 0.0650 USD — it has decreased by 8.71% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange International Stem Cell Corp. stocks are traded under the ticker ISCO.
International Stem Cell Corp. is going to release the next earnings report on May 16, 2024. Keep track of upcoming events with our Earnings Calendar.
ISCO stock is 16.34% volatile and has beta coefficient of −2.19. Check out the list of the most volatile stocks — is International Stem Cell Corp. there?
Yes, you can track International Stem Cell Corp. financials in yearly and quarterly reports right on TradingView.
ISCO stock has fallen by 35.00% compared to the previous week, the month change is a 29.85% fall, over the last year International Stem Cell Corp. has showed a 63.89% decrease.
ISCO net income for the last quarter is −458.00 K USD, while the quarter before that showed −131.00 K USD of net income which accounts for −249.62% change. Track more International Stem Cell Corp. financial stats to get the full picture.
Today International Stem Cell Corp. has the market capitalization of 680.77 K, it has increased by 19.62% over the last week.
No, ISCO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ISCO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade International Stem Cell Corp. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 29.00 employees. See our rating of the largest employees — is International Stem Cell Corp. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So International Stem Cell Corp. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating International Stem Cell Corp. stock shows the sell signal. See more of International Stem Cell Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. International Stem Cell Corp. EBITDA is −388.00 K USD, and current EBITDA margin is −6.02%. See more stats in International Stem Cell Corp. financial statements.